4-1BBL Enhances Anti-tumor Responses in the Presence or Absence of CD28 but CD28 Is Required for Protective Immunity against Parental Tumors
- 25 May 2001
- journal article
- Published by Elsevier BV in Cellular Immunology
- Vol. 210 (1), 56-65
- https://doi.org/10.1006/cimm.2001.1804
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Immunomodulatory Gene Therapy With Interleukin 12 and 4-1BB Ligand: Long- Term Remission of Liver Metastases in a Mouse ModelJNCI Journal of the National Cancer Institute, 2000
- T cell co-stimulatory molecules other than CD28Current Opinion in Immunology, 1999
- Differential Expression and Costimulatory Effect of 4-1BB (CD137) and CD28 Molecules on Cytokine-Induced Murine CD8+Tc1 and Tc2 CellsCellular Immunology, 1999
- OX-40: life beyond the effector T cell stageSeminars in Immunology, 1998
- NK1.1 Cells Express 4-1BB (CDw137) Costimulatory Molecule and Are Required for Tumor Immunity Elicited by Anti-4-1BB Monoclonal AntibodiesCellular Immunology, 1998
- Tumor necrosis factor receptor family members in the immune systemSeminars in Immunology, 1998
- Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathwayEuropean Journal of Immunology, 1998
- CD28/B7 SYSTEM OF T CELL COSTIMULATIONAnnual Review of Immunology, 1996
- 4‐1BB T‐cell antigen binds to mature B cells and macrophages, and costimulates anti‐μ‐primed splenic B cellsEuropean Journal of Immunology, 1994
- Molecular cloning of a ligand for the inducible T cell gene 4‐1BB: a member of an emerging family of cytokines with homology to tumor necrosis factorEuropean Journal of Immunology, 1993